ISSN: 2161-119X

Otolaryngology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Otolaryngol (Sunnyvale) 2017, Vol 7(5): 326
  • DOI: 10.4172/2161-119X.1000326

Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria

Paul L Swiecicki1*, Elliot Dickerson2, Emily Bellile3, Ashok Srinivasan4 and Francis P Worden1
1Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
2Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
3Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
4Department of Radiology, University of Michigan, Ann Arbor, MI, USA
*Corresponding Author : Paul L Swiecicki M.D, Comprehensive Cancer Center, University of Michigan, N13A23 N Ingalls Bldg, 300 N Ingalls St, SPC 5419, Ann Arbor MI, 48109, USA, Tel: 734-936-6884, Fax: 734-647-9480, Email: pswiecic@med.umich.edu

Received Date: Oct 12, 2017 / Accepted Date: Oct 23, 2017 / Published Date: Oct 30, 2017

Abstract

Objective: The purpose of this study was to explore the utility of the Choi Criteria in judging response to axitinib therapy in unresectable recurrent or distant metastatic head and neck squamous cell carcinoma.

Methods: Radiologic and clinical data was evaluated in a retrospective fashion from a single-arm phase II clinical trial of axitinib for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma. Twenty-nine patients had imaging to which the Choi Criteria were applied in an exploratory fashion. Responses rates by Choi Criteria were compared to those identified by RECIST v1.0 and statistical analyses were performed to evaluate significance. Association of best response to survival was also examined for each criteria (RECIST v1.0 and Choi).

Results: Application of the Choi Criteria demonstrated that 65.5% of patients achieved a partial response versus 6.9% by RECIST v1.0. Disease control rate was identical by Choi Criteria and RECIST v1.0 at 72.4%. Response to therapy based on Choi Criteria correlated to significantly improved estimated overall survival at 12 months (63% vs. 20%, p=0.03), whereas response to therapy based on RECIST was not a significant predictor of survival.

Conclusion: The Choi Criteria appear to better identify patients responding to therapy with the anti-angiogenic tyrosine kinase inhibitor axitinib versus RECIST v1.0 in this exploratory analysis. Use of the Choi Criteria to guide treatment decisions in further studies utilizing axitinib in this population may better identify patients benefiting from therapy.

Keywords: Head and neck neoplasm; Metastatic head and neck cancer; Axitinib; Vascular endothelial growth factor receptor; Choi Criteria; Imaging response criteria; Tyrosine kinase inhibitor

Citation: Swiecicki PL, Dickerson E, Bellile E, Srinivasan A, Worden FP (2017) Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria. Otolaryngol (Sunnyvale) 7:326. Doi: 10.4172/2161-119X.1000326

Copyright: © 2017 Swiecicki PL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Top